Hormonal
GLP-1 agonists (Liraglutide and Semaglutide) are promising interventions for reducing antipsychotic-induced weight gain, with Semaglutide showing superior efficacy to Liraglutide in general obesity populations, though evidence in SMI is still emerging.
GLP-1 medications like Liraglutide and Semaglutide show strong promise for counteracting weight gain from antipsychotics. Liraglutide has shown significant weight loss in SMI patients, and Semaglutide appears even more effective in general obesity studies. However, these require injections, which can be difficult for some patients, and more large-scale studies are needed to confirm long-term safety and efficacy in this specific group.
Liraglutide significantly reduced bodyweight compared to placebo (-5.3 kg)... Semaglutide was even more effective than liraglutide in reducing weight (-15.8% vs. -6.4%).
Why this rating
Strong data in general obesity, but limited and smaller sample sizes in SMI trials (n=103 and n=47).
Source
Antipsychotic‐induced weight gain: Is the weight over? New guidelines needed
Nini de Boer et al. · Acta Psychiatrica Scandinavica · 2022
DOI 10.1111/acps.13485
More from this paper
- Metformin is an effective and well-tolerated adjunctive pharmacological intervention for treating and preventing antipsychotic-induced weight gain in patients with severe mental illness.Good
- Switching antipsychotics to Aripiprazole results in significant weight reduction, but adding Aripiprazole to an existing regimen is not recommended due to increased risks of agitation and akathisia.Good
- Topiramate is effective for reducing antipsychotic-induced weight gain but is limited by poor tolerability, specifically cognitive difficulties and paresthesia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →